Toronto-based Axiom specializes in electronic data capture (EDC), data management, clinical trial management systems (CTMS), and electronic patient reported outcomes (ePRO) for biotechnology and pharmaceutical sponsors conducting clinical trials.
According to Noah Rhodes, managing director at Great Point Partners, Axiom has been growing at 56% per year over the last six years.
Green Point Partners, which has invested in the clinical trial service industry prior to this recapitalization, approached Axiom regarding the partnership.
While financial details of this recapitalization have not been disclosed, Andrew Schacter, founder and CEO of Axiom said in a statement that, “GPP’s investment will allow Axiom to increase the level of customer service and add additional technology solutions and services.”
